Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 85
Selected: 0
NCT IDTitle
NCT03813186Effect of Food on Blood Levels of ASTX727
NCT04637009A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
NCT00848601Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
NCT00005874Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
NCT03306264Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
NCT04061421Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
NCT04466514A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029
NCT00006047Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide
NCT00878423Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
NCT02348489SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
NCT01145989A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
NCT03075826A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
NCT00005869Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
NCT00042016Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT02998567Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
NCT00131313Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
NCT04953923Thorough QT Assessment of Cedazuridine in Healthy Subjects
NCT01712217A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
NCT01183949Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
NCT04479800Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers
NCT01239108Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
NCT01896856Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
NCT00032773Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
NCT01261312SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
NCT01652144A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
NCT04155580A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT00894894Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies
NCT00005873Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
NCT00522990Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
NCT00541034Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT03220477Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
NCT00005875Nitrocamptothecin in Treating Patients With Metastatic Melanoma
NCT00201721Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia
NCT05245682Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
NCT04013880ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT05456269A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS
NCT00881166Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors
NCT04655755Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
NCT03922555ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
NCT02103478Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
NCT00043381Decitabine Versus Supportive Care in Adults With Advanced-stage MDS
NCT01685268A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
NCT03019003Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
NCT01752933SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
NCT02901899Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT00042003Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT03875287Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
NCT00443976Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma
NCT05082259ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
NCT04134884Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer